Approvals· September 5, 2026 · 29 min read
Topic
Commercial Payer
Employer-sponsored and commercial plan coverage, PBM influence, utilization management, and affordability friction.
Approvals· September 4, 2026 · 36 min read
Lirafugratinib's Sept 27 PDUFA Does Not Rewrite Pemazyre PAs or Lytgobi CDx
By Ran Chen#PDUFA Date#FDA Approval#NDA Approval
Approvals· September 3, 2026 · 34 min read
Injectafer's Phosphate Boxed Warning Does Not Rewrite J1439, AP Generics, or Oral-Iron PAs
By Ran Chen#Boxed Warning#Label Warnings#FDA Approval
Approvals· September 2, 2026 · 33 min read
Aqneursa's Sept 19 A-T PDUFA Does Not Rewrite NPC-Only PAs or the 15 kg Floor
By Ran Chen#PDUFA Date#FDA Approval#NDA Approval
Pricing & Access· June 6, 2026 · 11 min read
Blue Cross Blue Shield GLP-1 coverage policy and exclusions in 2026
Pricing & Access· June 6, 2026 · 9 min read
CVS Caremark GLP-1 coverage and formulary changes for 2026
By Ran Chen#GLP-1#CVS Caremark#PBM
Pricing & Access· June 6, 2026 · 11 min read
Express Scripts GLP-1 formulary: NPF exclusions, PA criteria, and 2026 coverage rules
By Ran Chen#GLP-1#Express Scripts#Prior Authorization
Pricing & Access· June 6, 2026 · 12 min read
UnitedHealthcare GLP-1 coverage: PA criteria, reauth rules, and plan variations
By Ran Chen#GLP-1#UnitedHealthcare#UHC
Pricing & Access· June 5, 2026 · 15 min read
Rybelsus coverage guide: oral semaglutide access, formulary tiers, and prior authorization
By Ran Chen#GLP-1#Payer Coverage#Prior Authorization
Pricing & Access· June 4, 2026 · 13 min read
Ozempic prior authorization checklist for 2026
By Ran Chen#GLP-1#Prior Authorization#Payer Coverage